This Cambridge (UK) technology company is developing breakthrough treatments for rare diseases.
Healx today announced their $10 million Series A funding round, led by Balderton Capital, with participation from existing investors Jonathan Milner and Amadeus Capital.
Read Suranga's thoughts behind the investment on his Medium, with the story of how he first learned about Cambridge-based Healx.
Healx uses AI technology on a mission to give many of the 350 million sufferers of rare illnesses worldwide a better quality of life. There are approximately 7,000 rare diseases known globally and 95 per cent are without approved treatment. The company uses artificial intelligence, deep pharmacology expertise, and one of the largest collection of insights from rare disease patient groups to find new approaches to treating these rare diseases.
Healx works in close partnership with rare disease patient groups who are currently underserved by the traditional drug development model.